Thalidomide

Drug Profile

Thalidomide

Alternative Names: Alpha-N-phthalimidoglutarimide; FPF-300; K-17; NSC-66847; Synovir; Thaled; Thalidomide Celgene; Thalidomide Pharmion; Thalomid

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator EntreMed; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); University of Pennsylvania
  • Developer Celgene Corporation; Erkim; Fujimoto Pharmaceutical; Laphal; Weill Cornell Medical College
  • Class Antileprotics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Cachexia; Multiple myeloma; Aphthous stomatitis; Crohn's disease; Leprosy; Kaposi's sarcoma; Mycobacterial infections; Myelodysplastic syndromes; Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy; Multiple myeloma
  • Phase II Waldenstrom's macroglobulinaemia
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 03 May 2017 Celgene terminates a phase II trial due to low enrolment in Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT00538824)
  • 29 Apr 2016 Biomarkers information updated
  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top